Clinical Trial Update: A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People [Phase 3]

View source ↗

Summary

A Phase 3 study is recruiting to evaluate immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | Conditions: Pneumococcal Disease | Phase 3 | Status: RECRUITING